NASDAQ:SNOA - Sonoma Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $5.27 +0.09 (+1.74 %) (As of 02/28/2020 04:00 PM ET) Add Compare Today's Range$5.00Now: $5.27▼$5.5150-Day Range$4.22MA: $5.15▼$5.6952-Week Range$3.33Now: $5.27▼$10.35Volume46,675 shsAverage Volume15,781 shsMarket Capitalization$9.38 millionP/E RatioN/ADividend YieldN/ABeta0.66 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of chronic skin conditions and advanced tissue care in the United States and internationally. The company offers Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream indicated to relieve and manage the burning and itching associated with various skin conditions. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SNOA Previous Symbol CUSIPN/A CIK1367083 Webhttp://www.sonomapharma.com/ Phone707-283-0550Debt Debt-to-Equity Ratio0.07 Current Ratio3.33 Quick Ratio2.65Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$18.97 million Price / Sales0.49 Cash FlowN/A Price / Cash FlowN/A Book Value$6.31 per share Price / Book0.84Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-11,800,000.00 Net Margins-25.58% Return on Equity-44.11% Return on Assets-29.96%Miscellaneous Employees78 Outstanding Shares1,780,000Market Cap$9.38 million Next Earnings Date7/13/2020 (Estimated) OptionableNot Optionable Receive SNOA News and Ratings via Email Sign-up to receive the latest news and ratings for SNOA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:SNOA Rates by TradingView Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions What is Sonoma Pharmaceuticals' stock symbol? Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA." How were Sonoma Pharmaceuticals' earnings last quarter? Sonoma Pharmaceuticals Inc (NASDAQ:SNOA) released its quarterly earnings data on Thursday, November, 14th. The company reported ($0.91) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($1.18) by $0.27. The firm had revenue of $4.97 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 25.58% and a negative return on equity of 44.11%. View Sonoma Pharmaceuticals' Earnings History. When is Sonoma Pharmaceuticals' next earnings date? Sonoma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, July 13th 2020. View Earnings Estimates for Sonoma Pharmaceuticals. Has Sonoma Pharmaceuticals been receiving favorable news coverage? Media coverage about SNOA stock has been trending very negative on Saturday, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Sonoma Pharmaceuticals earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the next several days. View News Stories for Sonoma Pharmaceuticals. Are investors shorting Sonoma Pharmaceuticals? Sonoma Pharmaceuticals saw a drop in short interest in February. As of February 14th, there was short interest totalling 700 shares, a drop of 87.0% from the January 30th total of 5,400 shares. Based on an average trading volume of 27,200 shares, the short-interest ratio is presently 0.0 days. Approximately 0.1% of the shares of the stock are sold short. View Sonoma Pharmaceuticals' Current Options Chain. Who are some of Sonoma Pharmaceuticals' key competitors? Some companies that are related to Sonoma Pharmaceuticals include Alimera Sciences (ALIM), Guardion Health Sciences (GHSI), Adamis Pharmaceuticals (ADMP), RegeneRx Biopharmaceuticals (RGRX), Acer Therapeutics (ACER), Annovis Bio (ANVS), Evoke Pharma (EVOK), Fibrocell Science (FCSC), Moleculin Biotech (MBRX), Akari Therapeutics (AKTX), Jaguar Health (JAGX), China SXT Pharmaceuticals (SXTC), Celsion (CLSN), Pulmatrix (PULM) and Addex Therapeutics (ADDXF). What other stocks do shareholders of Sonoma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), VelocityShares Daily 2x VIX Short Term ETN (TVIX), Bristol-Myers Squibb (BMY), NovaBay Pharmaceuticals (NBY), Amarin (AMRN), Eyepoint Pharmaceuticals (EYPT), Fortress Biotech (FBIO), VBI Vaccines (VBIV), Verastem (VSTM) and Agenus (AGEN). Who are Sonoma Pharmaceuticals' key executives? Sonoma Pharmaceuticals' management team includes the folowing people: Mr. Frederick J. Sandford, CEO, Interim CFO & Director (Age 58)Mr. Marc Umscheid, Chief Operating Officer (Age 50)Dr. Robert Northey, Exec. VP of R&D (Age 62)Mr. Bruce Thornton, Exec. VP of International Operations & Sales (Age 55)Ms. Victoria Covel, Assistant Controller Who are Sonoma Pharmaceuticals' major shareholders? Sonoma Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.41%). Company insiders that own Sonoma Pharmaceuticals stock include James J Schutz and Robert E Miller. View Institutional Ownership Trends for Sonoma Pharmaceuticals. Which major investors are buying Sonoma Pharmaceuticals stock? SNOA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC. Company insiders that have bought Sonoma Pharmaceuticals stock in the last two years include James J Schutz and Robert E Miller. View Insider Buying and Selling for Sonoma Pharmaceuticals. How do I buy shares of Sonoma Pharmaceuticals? Shares of SNOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Sonoma Pharmaceuticals' stock price today? One share of SNOA stock can currently be purchased for approximately $5.27. How big of a company is Sonoma Pharmaceuticals? Sonoma Pharmaceuticals has a market capitalization of $9.38 million and generates $18.97 million in revenue each year. Sonoma Pharmaceuticals employs 78 workers across the globe.View Additional Information About Sonoma Pharmaceuticals. What is Sonoma Pharmaceuticals' official website? The official website for Sonoma Pharmaceuticals is http://www.sonomapharma.com/. How can I contact Sonoma Pharmaceuticals? Sonoma Pharmaceuticals' mailing address is 1129 NORTH MCDOWELL BLVD., PETALUMA CA, 94954. The company can be reached via phone at 707-283-0550 or via email at [email protected] MarketBeat Community Rating for Sonoma Pharmaceuticals (NASDAQ SNOA)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 211 (Vote Outperform)Underperform Votes: 202 (Vote Underperform)Total Votes: 413MarketBeat's community ratings are surveys of what our community members think about Sonoma Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNOA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNOA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/29/2020 by MarketBeat.com StaffFeatured Article: What is a portfolio manager?
